ClinicalTrials.gov
ClinicalTrials.gov Menu

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02352948
Recruitment Status : Active, not recruiting
First Posted : February 2, 2015
Last Update Posted : April 11, 2018
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 (durvalumab) versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 (durvalumab) plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements are not eligible for the study (prospective testing is not planned within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®).

Condition or disease Intervention/treatment Phase
Non - Small Cell Lung Cancer NSCLC Drug: MEDI4736 (durvalumab) Drug: Vinorelbine Drug: Gemcitabine Drug: Erlotinib Drug: MEDI4736 (durvaluman) in combination with tremelimumab (anti-CTLA4) Drug: tremelimumab (anti-CTLA4) Phase 3

Detailed Description:
The study has an umbrella design with 2 sub-studies in: sub-study A (randomizing patients with PD-L1 positive tumours 1:1 into MEDI4736 (durvalumab) vs. Standard of Care) and sub-study B (randomizing patients with PD-L1 negative tumours 2:3:1:2 into MEDI4736 (durvalumab) vs. MEDI4736 (durvalumab) plus tremelimumab vs. tremelimumab vs. Standard of Care. Two substudies may have different duration of recruitment period due difference in patients population (PD-L1 expression). They may not run concurrently with start and completion of recruitment potentially occuring at different time points.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 597 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Open Label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC).
Actual Study Start Date : January 13, 2015
Actual Primary Completion Date : February 9, 2018
Estimated Study Completion Date : December 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Durvalumab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: MEDI4736 (durvalumab) monotherapy in Sub-study A
MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.
Drug: MEDI4736 (durvalumab)
MEDI4736 (durvalumab) treatment by intravenous infusion
Active Comparator: Standard of Care in Sub-study A
Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.
Drug: Vinorelbine
Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
Drug: Gemcitabine
Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
Drug: Erlotinib
Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
Experimental: MEDI4736 (durvalumab) + tremelimumab in Sub-study B
MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
Drug: MEDI4736 (durvaluman) in combination with tremelimumab (anti-CTLA4)
MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion
Active Comparator: Standard of Care in Sub-study B
Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.
Drug: Vinorelbine
Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
Drug: Gemcitabine
Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
Drug: Erlotinib
Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
Experimental: MEDI4736 (durvalumab) monotherapy in Sub-study B
MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
Drug: MEDI4736 (durvalumab)
MEDI4736 (durvalumab) treatment by intravenous infusion
Experimental: tremelimumab in Sub-study B
tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
Drug: tremelimumab (anti-CTLA4)
tremelimumab (anti-CTLA4) treatment by intravenous infusion



Primary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: up to 3 years after first patient randomized ]
  2. Progression Free Survival (PFS) [ Time Frame: up to 3 years after the first patient randomized ]

Secondary Outcome Measures :
  1. Proportion of patients alive at 12 months from randomization (OS12) [ Time Frame: up to 1 year after last patient randomized ]
  2. Objective Response Rate (ORR) [ Time Frame: up to 3 years after the first patient randomized ]
  3. Duration of Response (DoR) [ Time Frame: up to 3 years after the first patient randomized ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 130 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged at least 18 years
  • Documented evidence of NSCLC (Stage IIIB/ IV disease)
  • Disease progression or recurrence after both a platinum-based chemotherapy regimen and at least 1 additional regimen for treatment of NSCLC
  • World Health Organization (WHO) Performance Status of 0 or 1
  • Estimated life expectancy more than 12 weeks

Exclusion Criteria:

  • Prior exposure to any anti-PD-1 or anti-PD-L1 antibody or anti CTLA4
  • Brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)
  • Active or prior documented autoimmune disease within the past 2 years
  • Evidence of severe or uncontrolled systemic disease, including active bleeding diatheses or active infections including hepatitis B, C and HIV
  • Any unresolved toxicity CTCAE (Common Terminology Criteria of Adverse Events) >Grade 2 from previous anti-cancer therapy
  • Known EGFR TK activating mutations or ALK rearrangements
  • Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1
  • Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02352948


  Show 203 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Paul Stockman, MBChB, PhD AstraZeneca

Additional Information:
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02352948     History of Changes
Other Study ID Numbers: D4191C00004
First Posted: February 2, 2015    Key Record Dates
Last Update Posted: April 11, 2018
Last Verified: April 2018

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Gemcitabine
Erlotinib Hydrochloride
Vinorelbine
Tremelimumab
Vinblastine
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Protein Kinase Inhibitors
Antineoplastic Agents, Phytogenic
Tubulin Modulators